ARCHIVES

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Cancer Center, Cooperative Group Trials

April 27, 2007

In Brief: Hammer Reappointed chairman; Wyngaarden Names Ferguson of Baylor As OMAR Director

July 29, 1988

Also in this 8-page issue: Senate Labor-HHS finds an extra $1 billion for NIH; Appropriations Committee reports bill to Senate.

July 15, 2005

Avastin Improves Survival By 30 Percent In Advanced Non-Small Cell Lung Cancer

June 24, 2005

NCAB Member Pollin Organizes Minority Outreach Effort

January 4, 1991

Waksals Keep ImClone Jobs, BMS Pumps $200M Into C225

March 8, 2002